Imaging Cannabinoid CB1 Receptors in Alcohol Dependence
NCT ID: NCT00816439
Last Updated: 2018-07-05
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
101 participants
Study Classification
OBSERVATIONAL
Study Start Date
2008-12-29
Study Completion Date
2014-08-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The cannabinoid type 1 (CB1) receptor is a protein found in the brain that is involved with the effects of marijuana; it may also play a role in the effects of alcohol dependence and withdrawal. Earlier animal studies have shown that although long-term alcohol use decreases the number of CB1 receptors in the brain, the number returns to normal after alcohol use stops. This study will use positron emission tomography (PET) and magnetic resonance imaging (MRI) scans to trace a radioactive chemical called \[11C\]MePPEP, which can locate and measure the number of CB1 receptors in the brain. Researchers will study the CB1 receptors in the brains of people with alcohol dependence, and compare the results to the CB1 receptors in the brains of people without alcohol dependence. The results of this study will be used to further research into appropriate treatment procedures for alcohol dependence.
This study will include 30 men with alcohol dependence and 50 men without alcohol dependence. All of the men must be between 18 and 65 years of age. Participants in both groups must not have any medical conditions that will prevent them from undergoing PET or MRI scans.
For the PET scan, participants will be injected with a small amount of \[11C\]MePPEP and will then be brought to the PET scanner. The scan will take between 3 and 4 hours, but participants will be allowed to take breaks over the course of the scan. The MRI scan will not require any injections and will take approximately 1 hour to complete.
Participants without alcohol dependence will make three visits to the National Institutes of Health Clinical Center. Blood and urine samples will be taken during one visit, and participants will arrange to have an MRI scan on one visit and a PET scan on the other visit, in whichever order they prefer.
Participants with alcohol dependence will undergo two PET scans: the first will be performed between 3 and 7 days after the participant last consumed alcohol, and the second will be performed approximately 2 to 4 weeks after the first scan (with no alcohol consumption permitted in the interval). Participants will alcohol dependence will also undergo an MRI scan and will provide blood and urine samples.
This study will include 30 men with alcohol dependence and 50 men without alcohol dependence. All of the men must be between 18 and 65 years of age. Participants in both groups must not have any medical conditions that will prevent them from undergoing PET or MRI scans.
For the PET scan, participants will be injected with a small amount of \[11C\]MePPEP and will then be brought to the PET scanner. The scan will take between 3 and 4 hours, but participants will be allowed to take breaks over the course of the scan. The MRI scan will not require any injections and will take approximately 1 hour to complete.
Participants without alcohol dependence will make three visits to the National Institutes of Health Clinical Center. Blood and urine samples will be taken during one visit, and participants will arrange to have an MRI scan on one visit and a PET scan on the other visit, in whichever order they prefer.
Participants with alcohol dependence will undergo two PET scans: the first will be performed between 3 and 7 days after the participant last consumed alcohol, and the second will be performed approximately 2 to 4 weeks after the first scan (with no alcohol consumption permitted in the interval). Participants will alcohol dependence will also undergo an MRI scan and will provide blood and urine samples.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals
NCT00158249
Marijuana Abuse
COMPLETED
PHASE2
Characterization Imaging Instruments in Alcoholics and Non-Alcoholics
NCT02108080
Alcohol Dependence
Alcohol Drinking
Alcohol-Related Disorders
+2 more
RECRUITING
The Neural Correlates of Cannabis Use
NCT03104257
Cannabis Dependence
Healthy
COMPLETED
Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder
NCT06512389
Alcohol Use Disorder
RECRUITING
PHASE2
Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder
NCT05859347
Cannabis Use Disorder
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Alcohol dependence (alcoholism) is a chronic medical illness with a relapsing course and a major public health problem. Alcoholism is clinically characterized by periods of uncontrolled alcohol consumption and withdrawal, during which counter-adaptive mechanisms such as stress and dysphoria are recruited. Neurobiological research into the pathophysiology of the illness suggest that both the primary rewarding effects of ethanol as well as neuroadaptive changes that occur during chronic alcohol exposure involve persistent changes in various brain neurotransmission systems, such as the dopamine, glutamate, and gamma-amino butyric acid (GABA) systems. Recent views of the illness also emphasize the long-lasting recruitment of the brain stress system. Unfortunately, despite this progress, available pharmacological agents for the treatment of alcoholism are too few and not sufficiently efficacious.
The brain endocannabinoid (EC) system is a recently discovered brain neurotransmission system, which involves endogenous cannabinoid agents (ECs) that act upon specific receptors (CB1 and CB2). CB1 receptor is abundant in the human brain and acts as an inhibitory modulator of classical neurotransmitters. ECs and CB1 receptors appear to modulate the brain reward system, and animal studies have demonstrated an important role of CB1 receptor stimulation in alcohol- and drug-related behaviors. During chronic alcohol exposure, EC levels in the brain are elevated and CB1 receptor levels are consequently reduced; this appears to be reversible following withdrawal. Animal studies suggest that CB1 receptor blockade in the abstinent phase may reduce alcohol craving and relapse. To what extent ECs and CB1 receptors are involved in the pathophysiology of alcohol dependence in humans is currently unknown. The lack of suitable methods to reliably quantify CB1 receptors in the living human brain has to date hindered the progress in this field.
In this protocol, we outline studies aiming at elucidating the role of CB1 receptors in alcohol and cannabis dependence by using positron emission tomography (PET) and the recently developed radiotracer for CB1 receptors, \[(18)F\]FMPEP-d2. The aim of this project is to explore CB1 receptor abnormalities at various stages of alcohol and cannabis dependence in humans. For the studies in alcohol dependence, the primary hypothesis is that CB1 receptors are downregulated during chronic alcohol exposure and upregulated during extended abstinence. For the studies in cannabis users, our primary hypothesis is that CB1 receptors are downregulated during chronic cannabis use and upregulated during extended abstinence. Insight into the role of CB1 receptor function in human alcoholism and in chronic cannabis use may help guide future development of pharmacotherapies.
The brain endocannabinoid (EC) system is a recently discovered brain neurotransmission system, which involves endogenous cannabinoid agents (ECs) that act upon specific receptors (CB1 and CB2). CB1 receptor is abundant in the human brain and acts as an inhibitory modulator of classical neurotransmitters. ECs and CB1 receptors appear to modulate the brain reward system, and animal studies have demonstrated an important role of CB1 receptor stimulation in alcohol- and drug-related behaviors. During chronic alcohol exposure, EC levels in the brain are elevated and CB1 receptor levels are consequently reduced; this appears to be reversible following withdrawal. Animal studies suggest that CB1 receptor blockade in the abstinent phase may reduce alcohol craving and relapse. To what extent ECs and CB1 receptors are involved in the pathophysiology of alcohol dependence in humans is currently unknown. The lack of suitable methods to reliably quantify CB1 receptors in the living human brain has to date hindered the progress in this field.
In this protocol, we outline studies aiming at elucidating the role of CB1 receptors in alcohol and cannabis dependence by using positron emission tomography (PET) and the recently developed radiotracer for CB1 receptors, \[(18)F\]FMPEP-d2. The aim of this project is to explore CB1 receptor abnormalities at various stages of alcohol and cannabis dependence in humans. For the studies in alcohol dependence, the primary hypothesis is that CB1 receptors are downregulated during chronic alcohol exposure and upregulated during extended abstinence. For the studies in cannabis users, our primary hypothesis is that CB1 receptors are downregulated during chronic cannabis use and upregulated during extended abstinence. Insight into the role of CB1 receptor function in human alcoholism and in chronic cannabis use may help guide future development of pharmacotherapies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Alcoholism
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
ALCOHOL DEPENDENT SUBJECTS:
1. All subjects must be male, 18-65 years of age and be able to give written informed consent.
2. All subjects must be healthy based on history and physical examination.
3. Subjects must fulfill DSM-IV criteria (American Psychiatric Association 1987) for alcohol dependence. In addition, they must have an alcohol consumption of 35 or more standard drinks per week, as measured by timeline follow-back during the 28-day period preceding admission, as well as during the 7-day period immediately preceding it.
4. About half of the patients with alcohol dependence will be carriers of the C allele of the rs2023239 SNP and half will not.
HEALTHY SUBJECTS:
1. All subjects must be male, 18-65 years of age and be able to give written informed consent.
2. This comparison group must be healthy based on history and physical examination.
3. About half of the healthy subjects will currently smoke cigarettes and about half will not.
4. About half of the healthy subjects will be carriers of the C allele of the rs2023239 SNP and half will not.
CANNABIS USERS:
1. All subjects must be male, 18-65 years of age and be able to give written informed consent.
2. All subjects must be healthy based on history and physical examination.
3. Self-reported cannabis use of at least one year with a typical pattern of use of at least 5 days per week for the six months prior to unit admission.
4. A positive urine cannabinoid test within 90 days of admission.
1. All subjects must be male, 18-65 years of age and be able to give written informed consent.
2. All subjects must be healthy based on history and physical examination.
3. Subjects must fulfill DSM-IV criteria (American Psychiatric Association 1987) for alcohol dependence. In addition, they must have an alcohol consumption of 35 or more standard drinks per week, as measured by timeline follow-back during the 28-day period preceding admission, as well as during the 7-day period immediately preceding it.
4. About half of the patients with alcohol dependence will be carriers of the C allele of the rs2023239 SNP and half will not.
HEALTHY SUBJECTS:
1. All subjects must be male, 18-65 years of age and be able to give written informed consent.
2. This comparison group must be healthy based on history and physical examination.
3. About half of the healthy subjects will currently smoke cigarettes and about half will not.
4. About half of the healthy subjects will be carriers of the C allele of the rs2023239 SNP and half will not.
CANNABIS USERS:
1. All subjects must be male, 18-65 years of age and be able to give written informed consent.
2. All subjects must be healthy based on history and physical examination.
3. Self-reported cannabis use of at least one year with a typical pattern of use of at least 5 days per week for the six months prior to unit admission.
4. A positive urine cannabinoid test within 90 days of admission.
Exclusion Criteria
ALCOHOL DEPENDENT PATIENTS:
1. Any serious medical condition as judged by the investigator in consultation with the attending physician in the NIAAA program.
2. Clinically significant coagulopathies or laboratory abnormalities other than those related to alcohol dependence.
Past or present diagnosis of schizophrenia, bipolar illness or any other psychotic disorder; any current disorder that has required psychoactive medication (other than oxazepam) within the preceding 28-day period (42 days for fluoxetine). 3. Oxazepam is a relatively short acting benzodiazepine and is used clinically during alcohol withdrawal. Any present substance abuse other than alcohol.
4\. Positive test for HIV.
5\. Metallic foreign bodies that would be affected by the MRI scanner magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan.
6\. Head trauma resulting in a period of unconsciousness lasting longer than 1 hour.
7\. History of fetal alcohol syndrome or other neurodevelopmental disorder.
8\. History of seizures, other than in childhood and related to fever.
9\. Recent exposure to radiation (i.e., PET from other research) which when combined with this study would be above the allowable limits.
10\. Positive urine drug screen.
11\. Inability to lie flat on camera bed for about 2.5 h
HEALTHY SUBJECTS:
1. Any current Axis I diagnosis; and any lifetime diagnosis of drug abuse or dependence.
2. Clinically significant laboratory abnormalities.
3. Recent heavy use of alcohol. That is, subjects must have an alcohol audit score of less than or equal to 9. In addition, subjects must agree not to consume any alcohol in the three days prior to the PET scan.
4. Psychotropic medication use (including benzodiazepines and illicit drugs) during the 28 days (42 day for fluoxetine) prior to the PET scan.
5. Serious medical problems.
6. Positive test for HIV.
7. Metallic foreign bodies that would be affected by the MRI magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan.
8. Head trauma resulting in a period of unconsciousness lasting longer than 10 minutes.
9. History of fetal alcohol syndrome or other neurodevelopmental disorder.
10. History of seizures, other than in childhood and related to fever.
11. Recent exposure to radiation (i.e., PET from other research) which when combined with this study would be above the allowable limits.
12. Positive urine drug screen.
13. Inability to lie flat on camera bed for about 2.5 h
1. History or presence of any clinically significant illness, as determined by history, physical examination, and/or laboratory tests.
2. Past or present diagnosis of schizophrenia, bipolar illness or any other psychotic disorder; any current disorder that has required psychoactive medication within the preceding 28-day period (42 days for fluoxetine).
3. Current physical dependence on any substance other than cannabis, nicotine, or caffeine;
4. Positive test for HIV.
5. Metallic foreign bodies that would be affected by the MRI scanner magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan.
6. Head trauma resulting in a period of unconsciousness lasting longer than 10 minutes.
7. History of fetal alcohol syndrome or other neurodevelopmental disorder.
8. History of seizures, other than in childhood and related to fever.
9. Recent exposure to radiation (i.e., PET from other research) which when combined with this study would be above the allowable limits.
10. Inability to lie flat on camera bed for about 2.5 h.
11. Regular use of alcohol (greater than or equal to 6 standard drinks per day) four or more times per week in the month prior to study entry.
12. Currently interested in or participating in drug abuse treatment, or participated in drug abuse treatment within 60 days preceding study enrollment.
1. Any serious medical condition as judged by the investigator in consultation with the attending physician in the NIAAA program.
2. Clinically significant coagulopathies or laboratory abnormalities other than those related to alcohol dependence.
Past or present diagnosis of schizophrenia, bipolar illness or any other psychotic disorder; any current disorder that has required psychoactive medication (other than oxazepam) within the preceding 28-day period (42 days for fluoxetine). 3. Oxazepam is a relatively short acting benzodiazepine and is used clinically during alcohol withdrawal. Any present substance abuse other than alcohol.
4\. Positive test for HIV.
5\. Metallic foreign bodies that would be affected by the MRI scanner magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan.
6\. Head trauma resulting in a period of unconsciousness lasting longer than 1 hour.
7\. History of fetal alcohol syndrome or other neurodevelopmental disorder.
8\. History of seizures, other than in childhood and related to fever.
9\. Recent exposure to radiation (i.e., PET from other research) which when combined with this study would be above the allowable limits.
10\. Positive urine drug screen.
11\. Inability to lie flat on camera bed for about 2.5 h
HEALTHY SUBJECTS:
1. Any current Axis I diagnosis; and any lifetime diagnosis of drug abuse or dependence.
2. Clinically significant laboratory abnormalities.
3. Recent heavy use of alcohol. That is, subjects must have an alcohol audit score of less than or equal to 9. In addition, subjects must agree not to consume any alcohol in the three days prior to the PET scan.
4. Psychotropic medication use (including benzodiazepines and illicit drugs) during the 28 days (42 day for fluoxetine) prior to the PET scan.
5. Serious medical problems.
6. Positive test for HIV.
7. Metallic foreign bodies that would be affected by the MRI magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan.
8. Head trauma resulting in a period of unconsciousness lasting longer than 10 minutes.
9. History of fetal alcohol syndrome or other neurodevelopmental disorder.
10. History of seizures, other than in childhood and related to fever.
11. Recent exposure to radiation (i.e., PET from other research) which when combined with this study would be above the allowable limits.
12. Positive urine drug screen.
13. Inability to lie flat on camera bed for about 2.5 h
1. History or presence of any clinically significant illness, as determined by history, physical examination, and/or laboratory tests.
2. Past or present diagnosis of schizophrenia, bipolar illness or any other psychotic disorder; any current disorder that has required psychoactive medication within the preceding 28-day period (42 days for fluoxetine).
3. Current physical dependence on any substance other than cannabis, nicotine, or caffeine;
4. Positive test for HIV.
5. Metallic foreign bodies that would be affected by the MRI scanner magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan.
6. Head trauma resulting in a period of unconsciousness lasting longer than 10 minutes.
7. History of fetal alcohol syndrome or other neurodevelopmental disorder.
8. History of seizures, other than in childhood and related to fever.
9. Recent exposure to radiation (i.e., PET from other research) which when combined with this study would be above the allowable limits.
10. Inability to lie flat on camera bed for about 2.5 h.
11. Regular use of alcohol (greater than or equal to 6 standard drinks per day) four or more times per week in the month prior to study entry.
12. Currently interested in or participating in drug abuse treatment, or participated in drug abuse treatment within 60 days preceding study enrollment.
Minimum Eligible Age
18 Years
Maximum Eligible Age
65 Years
Eligible Sex
MALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
Sponsor Role
lead
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert B Innis, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Mental Health (NIMH)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Basavarajappa BS, Hungund BL. Role of the endocannabinoid system in the development of tolerance to alcohol. Alcohol Alcohol. 2005 Jan-Feb;40(1):15-24. doi: 10.1093/alcalc/agh111. Epub 2004 Nov 18.
Reference Type
BACKGROUND
Brown AK, George DT, Fujita M, Liow JS, Ichise M, Hibbeln J, Ghose S, Sangare J, Hommer D, Innis RB. PET [11C]DASB imaging of serotonin transporters in patients with alcoholism. Alcohol Clin Exp Res. 2007 Jan;31(1):28-32. doi: 10.1111/j.1530-0277.2006.00261.x.
Reference Type
BACKGROUND
Cippitelli A, Bilbao A, Hansson AC, del Arco I, Sommer W, Heilig M, Massi M, Bermudez-Silva FJ, Navarro M, Ciccocioppo R, de Fonseca FR; European TARGALC Consortium. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. Eur J Neurosci. 2005 Apr;21(8):2243-51. doi: 10.1111/j.1460-9568.2005.04056.x.
Reference Type
BACKGROUND
Hirvonen J, Zanotti-Fregonara P, Gorelick DA, Lyoo CH, Rallis-Frutos D, Morse C, Zoghbi SS, Pike VW, Volkow ND, Huestis MA, Innis RB. Decreased Cannabinoid CB1 Receptors in Male Tobacco Smokers Examined With Positron Emission Tomography. Biol Psychiatry. 2018 Nov 15;84(10):715-721. doi: 10.1016/j.biopsych.2018.07.009. Epub 2018 Jul 21.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-M-0040
Identifier Type: -
Identifier Source: secondary_id
090040
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors
NCT01625611
COMPLETED
PHASE1
Clinical Intervention in Alcohol Use Disorder
NCT02168400
COMPLETED
NA
Effects of Cannabidiol in Alcohol Use Disorder
NCT03252756
COMPLETED
PHASE1/PHASE2
Cerebellar Alterations in Individuals With a Cannabis Use Disorder
NCT02816034
COMPLETED
NA
The Effects of Treatment With Naltrexone in Alcohol and Cannabis-dependent Patients
NCT01560013
UNKNOWN
NA
Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse
NCT02616094
COMPLETED
NA
Neurobiology of Alcohol and Nicotine Co-Addiction
NCT03338933
COMPLETED
Serotonin Transporters in Alcoholism
NCT00085865
COMPLETED
Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults
NCT00656487
COMPLETED
PHASE2
Using Imaging to Assess Effects of THC on Brain Activity
NCT03655717
COMPLETED
NA
VRT as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use
NCT03662737
COMPLETED
Cannabidiol in Youth Alcohol Use Disorder
NCT05317546
COMPLETED
PHASE2
Cannabidiol for Alcohol Use Disorder
NCT03904849
WITHDRAWN
PHASE1/PHASE2
Brain Functional Connectivity in Alcohol Use Disorder
NCT02877849
COMPLETED
Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment
NCT05855668
RECRUITING
NA
Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving
NCT07148843
NOT_YET_RECRUITING
PHASE2/PHASE3
CBD for the Treatment of Alcohol Use Disorder
NCT04873453
COMPLETED
PHASE2
Multimodal Neuroimaging of Alcohol Cues, Cortisol Response, and Compulsive Motivation
NCT04412824
COMPLETED
EARLY_PHASE1
Serotonin in Alcoholism
NCT00011752
COMPLETED
The Efficacy and Neurobehavioural Mechanism of Cannabidiol (CBD) for Alcohol Dependence
NCT05387148
UNKNOWN
PHASE2
Metabolism in the Human Brain Following Consumption of a Keto-ester in Alcohol Use Disorder (AUD) With Proton Magnetic Resonance Spectroscopic Imaging (MRSI)
NCT05937893
COMPLETED
NA
Neurofeedback & Alcohol Dependence
NCT02486900
COMPLETED
NA
Alcohol, Behavior, and Brain Imaging
NCT03930446
COMPLETED
EARLY_PHASE1
The Effect of Positive and Negative Emotions on Brain Activity in Alcoholics and Nonalcoholics
NCT00001675
COMPLETED
Cannabis Effects on Brain Morphology in Aging
NCT01874886
COMPLETED